APOLLO trial milestone puts Disc Medicine in focus

Disc Medicine (IRON) drew investor attention after announcing that the last participant has been randomized and dosed in its pivotal Phase 3 APOLLO study of bitopertin in erythropoietic protoporphyria, with enrollment expanded to 183 patients.

The APOLLO milestone arrives after a mixed stretch for the stock, with a 4.8% 7 day share price return but a 22.8% 90 day share price decline. At the same time, the 3 year total shareholder return of about 18x highlights how long term holders have still seen strong gains.

If this kind of catalyst driven move has your attention, it could be a good moment to widen your watchlist and scan 36 healthcare AI stocks

With shares down about 23% over 90 days but still carrying a very large 3 year total return and trading below the average analyst price target, investors may ask whether this is a fresh entry point or whether the market is already pricing in future growth.

Price to book and DCF are sending different signals

Disc Medicine closed at $62.01, while the SWS DCF model estimates a future cash flow value of $132.24, implying the shares trade at a large discount to that model. That sits alongside a P/B ratio of 3.2x, which screens as good value against direct peers at 12.1x but looks expensive versus the broader US biotechs industry at 2.5x.

The DCF approach works by projecting a company’s future cash flows and discounting them back to today using a required rate of return. For a clinical stage biotech with no current revenue and a net loss of $212.184m, this kind of model leans heavily on assumptions about future trial outcomes, approvals and eventual commercialization.

For context, Disc Medicine is currently unprofitable and is not forecast to achieve profitability over the next 3 years, and it reports less than $1m in revenue. That profile is common among early and mid stage biotech names, where valuation often reflects expectations around a pipeline, such as bitopertin and other hematology candidates, rather than current financials.

Result: DCF fair value of $132.24 (UNDERVALUED)

However, you also need to weigh clear risks, including trial or regulatory setbacks for bitopertin, as well as ongoing losses with revenue still reported as $0.

Profits, returns and insider moves send a mixed message

For anyone looking at Disc Medicine today, the trade off is clear. The company makes less than $1m in revenue, reports a net loss of $212.184m and is not expected to reach profitability within 3 years. Yet the share price is still 53.1% below the SWS estimate of fair value and the stock has delivered an 18.1x total return over 3 years.

That mix of long term gains and ongoing losses shows up in other metrics too. Return on equity is negative at 28.68% and losses have increased at a rate of 40.2% per year over the past 5 years. Analysts see no revenue next year and forecasts are not tightly aligned, even though the average price target of $100.17 sits more than 20% above the current $62.01 share price.

On governance, the picture is more balanced. The board is considered experienced, with an average tenure of 5.4 years and 50% independence, and management tenure averages 2.6 years. However, CEO total compensation of $9.07m is above the $5.40m peer group average and has risen while the company remains unprofitable.

Ownership signals may also give you pause. There has been significant insider selling over the past 3 months, and all reported liabilities are from higher risk funding sources rather than customer deposits. That structure can add financial pressure if capital markets conditions change or clinical timelines are extended.

Stepping back, Disc Medicine has outperformed the broader US market over 1 year but lagged the US biotechs industry. It remains a pre revenue, loss making name whose valuation hinges on clinical outcomes. For many investors, the key question is whether the current discount and hematology pipeline are enough to justify those funding, profitability and execution risks.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Disc Medicine for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 61 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With sentiment split between risks and rewards, this is a moment to move quickly, review the facts for yourself, and weigh the trade off using 1 key reward and 3 important warning signs

Looking for more investment ideas?

If Disc Medicine is on your radar, do not stop there. Use this moment to scan other opportunities and make sure you are not missing stronger fits for your portfolio.

• Target reliable income prospects by reviewing companies highlighted in the 12 dividend fortresses and see which yields might complement a growth focused holding like IRON.
• Spot potential value candidates before they are widely followed by checking the screener containing 25 high quality undiscovered gems and comparing their fundamentals with the biotechs already on your list.
• Prioritize resilience and capital preservation by filtering for companies in the 69 resilient stocks with low risk scores and use them to balance higher risk, trial driven positions.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.